In the article, the researchers wrote that infection with the Zika virus “augmented the death of fNSC in the neurospheres, in proportion to their size.” This led to a drop in fNSC proliferation, which is the process of cell growth and division that is imperative to fetal development. The researchers continued, “These results show that ZIKV infection not only induces the death of human fNSCs but also impairs their proliferation and clonal expansion in neurospheres.”
Additionally, the researchers found that Zika infection prompted the autophagy, or natural cell destruction, of fNSCs, leading to an increase of viral replication and thus a higher viral load. Together, NS4A and NS4B decreased fNSC proliferation by 64.7%. However, the researchers noted that expression of these proteins in fNSCs, either together or separately, do not lead to programmed cell death, meaning that the proteins are “not toxic to cells;" rather, “mitotic neurogenesis of fNSCs is selectively and substantially impaired by ZIKV NS4A and NS4B when these proteins are ectopically expressed individually and in combination.” The researchers noted that, while not toxic, the proteins inhibit Akt-mTOR signaling, which is critical for fNSC neurogenesis and autophagy induction.
In a USC news release
, Zhen Zhao, PhD, corresponding co-author, assistant professor of research physiology and biophysics at USC, stated that future research involving NS4A and NS4B Zika proteins will focus on identifying a cure for Zika-related microcephaly. Jae Jung, PhD, senior corresponding author, distinguished professor and chair of the Department of Microbiology and Immunology, Keck School of Medicine at USC, added, “We now know the molecular pathway, so we made the first big step toward target therapy for Zika-induced microcephaly…Years from now, one shot or a series of shots could target the proteins NS4A and NS4B or their collaborators.”
Transmission Through Blood Transfusions
Although primarily transmitted by the mosquito vector
, Zika, dengue and chikungunya can all be transmitted through blood transfusions in rare cases, according to the Centers for Disease Control and Prevention (CDC). Recent reports
from Brazil indicate that a blood donor is suspected to have transmitted the infection to two hospital patients in late January: a 54-year-old patient with myelofibrosis, a bone marrow disorder, and a 14-year-old leukemia patient. The donor reported Zika-like symptoms two days after donating blood; the individual later tested positive for Zika. Further testing proved that the viral strain from the two patients matched that of the donor; however, neither patients exhibited any signs or symptoms of Zika infection.
Prior to these findings being published
in the New England Journal of Medicine
, US officials were aware of the possibility of infection through blood transfusion, and so, when active Zika transmission was suspected in Florida, the US Food and Drug Administration (FDA) urged blood establishments to cease blood collection in the areas with the non–travel-related Zika-infected patients. Active transmission was later confirmed
in Miami, Florida, and cases are currently up to 35, with one additional case locally infected in Miami and exported into Texas
by the infected individual.
There are currently no FDA-approved Zika vaccines available to prevent infection, although several are in clinical trials
. To avoid infection, the CDC recommends using DEET-containing mosquito repellents, covering exposed skin, and using window and door screens to avoid mosquito bites.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.